You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rituximab

Showing 1 - 25 of 1,111
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Rituximab in Children With Blood Diseases

Not yet recruiting
  • Rituximab
  • +2 more
  • Rituximab
  • Rituximab (once a week)
  • (no location specified)
Apr 8, 2022

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)

Not yet recruiting
  • Splenic Marginal Zone Lymphoma
  • Aarhus, Denmark
  • +4 more
Feb 17, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022

Prognostic Model of Rituximab in the Treatment of MN

Not yet recruiting
  • Idiopathic Membranous Nephropathy
  • Rituximab
  • (no location specified)
Dec 28, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Pharmacological Action Trial (Rituximab, Dexamethasone)

Not yet recruiting
  • Pharmacological Action
  • (no location specified)
Sep 22, 2022

Nephrotic Syndrome in Children, Rituximab Trial in Hangzhou (Rituximab, Steroid)

Not yet recruiting
  • Nephrotic Syndrome in Children
  • Rituximab
  • Hangzhou, Zhejiang, China
    Children's Hospital, Zhejiang University School of Medicine
Feb 9, 2023

Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Nov 22, 2022

Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)

Not yet recruiting
  • Idiopathic Membranous Nephropathy
  • (no location specified)
Aug 22, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Refractory Myasthenia Gravis, Rituximab Trial in Guangzhou (Rituximab)

Recruiting
  • Refractory Myasthenia Gravis
  • Rituximab
  • Rituximab
  • Guangzhou, China
    First Affiliated Hospital, Sun Yat-Sen University
Apr 26, 2022

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 4, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • (no location specified)
Nov 30, 2022

Schizophrenia Spectrum and Other Psychotic Disorders Trial in Örebro (Rituximab)

Not yet recruiting
  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Rituximab
  • Örebro, Sweden
    Örebro university hospital
Nov 21, 2022

APS Secondary to SLE

Recruiting
  • Antiphospholipid Syndrome
  • Jinan, Shandong, China
    Qilu Hospital
Nov 30, 2022

Idiopathic Membranous Nephropathy Trial in Beijing (Rituximab, Modified Ponticelli regimen)

Recruiting
  • Idiopathic Membranous Nephropathy
  • Rituximab
  • Modified Ponticelli regimen
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 23, 2023

Steroid-Dependent Nephrotic Syndrome Trial in Kolkata (Rituximab, Mycophenolate Mofetil)

Active, not recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Rituximab
  • Mycophenolate Mofetil
  • Kolkata, West Bengal, India
    Nilratan Sircar Medical College and Hospital
Apr 6, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022